StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) stock

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.78−0.16 (-1.61%)

Close on Nov 17, 2026Market cap $561.73MP/E –Yield –

Climb Bio price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Climb Bio's price to book ratio was 2.9× on Nov 11, 2026, against 0.7× a year earlier. Over the last 5 years it ranged from 0.4× to 4.2×, with a median of 0.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.9×+1.4
2025Dec 31, 20251.5×+1.0
2024Dec 31, 20240.6×−0.1
2023Dec 29, 20230.7×−0.0
2022Dec 30, 20220.7×−0.8
2021Dec 31, 20211.6×–

More Climb Bio figures

See a number that looks wrong?